Evaluation of Belimumab in Treatment of Chinese Childhood-Onset Systemic Lupus Erythematosus: a Prospective Analysis from a Multicentre Study
Li Wang,Xiaohua Liang,Zhilang Cao,Dahai Wang,Ying Luo,Yuan Feng,Chong Luo,Shufeng Zhi,Yiling Huang,Zhidan Fan,Chaoying Wang,Haimei Liu,Jinxiang Liu,Tianyu Zhang,Qiuting Cheng,Xue Xie,Lanjun Shuai,Zanhua Rong,Ping Zeng,Haiguo Yu,Meiping Lu,Li Sun,Sirui Yang,Dongmei Zhao,Wei Zhang,Xiaochuan Wu,Qiu Li,Yajun Wang,Qiuye Zhang,Jun Yang,Xiaoqing Li,Hongmei Song,Xuemei Tang
DOI: https://doi.org/10.1093/rheumatology/kead406
2024-01-01
Rheumatology
Abstract:Objective The aim of this study is to identify whether low lupus disease activity status (LLDAS) and clinical remission (CR) of belimumab plus standard of care (SoC) therapy are achievable goals in childhood-onset SLE (cSLE).Methods This multicentre, one arm pre-post intervention study was conducted at 15 centres in China. The primary end point was to describe the proportion of patients who achieved LLDAS and CR after 3, 6 and 12 months after treatment with belimumab plus SoC therapy. A multiple regression model was used to impute missing data. A Poisson regression model was used to calculate the effect of belimumab treatment on the reduced risk of serious diseases and the incidence of new damage.Result A total of 193 (92.2% female) with active cSLE from 15 centres were included. At 3, 6 and 12 months, the proportion of LLDAS (CR) was 12.4% (1.0%), 25.6% (4.5%) and 70.3% (29.7%), respectively. The mean SELENA-SLEDAI score decreased from 11.0 at baseline to 3.7, 2.9 and 1.7 at 3, 6 and 12 months. At baseline, all patients received steroids at a mean (s.d.) prednisone equivalent dose of 31.0 (18.2) mg/day, which decreased to 19.4 (10.8) mg/day at month 3, 12.6 (7.2) mg/day at month 6 and 6.7 (5.3) mg/day at month 12. The symptoms and immunological indicators were also significantly improved.Conclusion This is the first and largest sample size prospective clinical intervention study of cSLE patients treated with belimumab in China. LLDAS and CR were attainable treat-to-target of belimumab plus SoC therapy in cSLE.